Aldeyra Therapeutics: FDA Pivotal Decision on Reproxalap's Chamber Data

Aldeyra Therapeutics, a biotechnology company, is awaiting a pivotal FDA decision on Reproxalap for Dry Eye Disease and Allergic Conjunctivitis. Reproxalap is their lead asset, and they leverage their proprietary Reactive Aldehyde Species platform. The FDA decision follows positive chamber data, which could impact the treatment of these eye diseases.